Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Special Issues in Autoimmunity Reviews and Journal of Autoimmunity 
No comment yet.
Sign up to comment
Scoop.it!
Paolo Sfrisoa, , ,Francesco Casoa,Sofia Tognonb,Paola Galozzia,Alessandra Gavaa,Leonardo Punzia a Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italyb Ophthalmology Unit, Department of Neurosciences, University of Padova, Padova, Italy http://dx.doi.org/10.1016/j.autrev.2012.07.028,
Blau syndrome (BS) is a rare autosomal dominant, autoinflammatory syndrome characterized by the clinical triad of granulomatous recurrent uveitis, dermatitis and symmetric arthritis. The gene responsible for BS has been identified in the caspase recruitment domain gene CARD15/NOD2. In the majority of patients, the disease is characterized by early onset, usually before 3–4 years of age. The manifestations at disease onset are usually represented by articular and cutaneous involvement signs, generally followed later by ocular manifestations which are often the most relevant morbidity of BS. In some cases the presence of fever is also observed; atypical cases of BS have been reported with cardiovascular, neurological, renal, intestinal and other organ involvement. The rarity and the variations in the severity and evolution of its expressions do not permit sufficient data about optimal treatment for patients with BS. The first step of therapy is represented by the use of corticosteroids and successively, in case of unsatisfactory response, by additional treatment with immunosuppressive agents. The results with biologic anti-cytokine agents, such as anti-TNFα and anti-IL1β, are different, particularly with regard to ocular morbidity. Clinical and genetic aspects of the familial and the sporadic form of BS will be discussed and focused on. A description of a case study of an Italian family is also included. Blau syndrome, clinical and genetic aspects http://t.co/BALw5P69...
Scoop.it!
Autoinflammation and autoimmunity: Bridging the divide A. Doria, ,M. Zen,S. Bettio,M. Gatto,N. Bassi,L. Nalotto,A. Ghirardello,L. Iaccarino,L. Punzi Division of Rheumatology, Department of Medicine, University of Padova, Italy http://dx.doi.org/10.1016/j.autrev.2012.07.018
► AIDs are characterized by chronic activation of immune system (innate immunity). ► ADs are characterized by chronic activation of immune system (innate and adaptive). ► Inflammasome related genes are involved in the pathogenesis of AIDs and, probably, of ADs. ► AIDs and ADs are systemic diseases, frequently affecting skin, gut and musculoskeletal system. ► New biological therapies have reduced disease morbidities and improved prognosis of AIDs and ADs.
|
Scoop.it!
Alfredo Corell's insight:
Autoimmunity Reviews
Volume 12, Issue 11, September 2013, Pages 1076–1084 Benedetta Marigliano, Alessandra Soriano, Domenico Margiotta, Marta Vadacca, Antonella AfeltraAbstract The lungs are frequently involved in Connective Tissue Diseases (CTDs). Interstitial lung disease (ILD) is one of the most common pleuropulmonary manifestations that affects prognosis significantly. In practice, rheumatologists and other physicians tend to underestimate the impact of CTD-ILDs and diagnose respiratory impairment when it has reached an irreversible fibrotic stage. Early investigation, through clinical evidence, imaging and – in certain cases – lung biopsy, is therefore warranted in order to detect a possible ILD at a reversible initial inflammatory stage. In this review, we focus on lung injury during CTDs, with particular attention to ILDs, and examine their prevalence, clinical manifestations and histological patterns, as well as therapeutic approaches and known complications till date. Although several therapeutic agents have been approved, the best treatment is still not certain and additional trials are required, which demand more knowledge of pulmonary involvement in CTDs. Our central aim is therefore to document the impact that lung damage has on CTDs. We will mainly focus on Rheumatoid Arthritis (RA), which – unlike other rheumatic disorders – resembles Idiopathic Pulmonary Fibrosis (IPF) in numerous aspects.
Gilbert C FAURE's curator insight,
December 15, 2013 11:32 AM
rheumatoid lung is histologicaly frequent according to some autopsy studies but seldomly clinically diagnosed already 4 pages of scoops related to rheumatoid arthritis http://www.scoop.it/t/rheumatology-rhumatologie?q=rheumatoid+art
Scoop.it!
Alberto Martini, Dipartimento di Pediatria, Università di Genova, Pediatria II e Reumatologia, Istituto G Gaslini, Genova, Italy http://dx.doi.org/10.1016/j.autrev.2012.07.022,
Systemic juvenile idiopathic arthritis (sJIA) sets well apart from all the other forms of JIA. Several observations show that sJIA is etiopathogenically different from all the other forms of JIA and has a prominent autoinflammatory component. A major role in the pathogenesis is played by two proinflammatory cytokines, interleukin-6 and interleukin-1. The specific inhibition of these two cytokines is going to change not only the therapeutic approach to the disease but also, presumably, its long term prognosis.
|
Special Issues in Autoimmunity Reviews and Journal of Autoimmunity
Autoimmunity Reviews and the Journal of Autoimmunity both feature a special issue on diagnostic criteria in autoimmune diseases, to coincide with the 9th International Congress on Autoimmunity in Nice, France, in March 2014.
Here you can read both issues – free access until June 2014.
Diagnostic Criteria in Autoimmune Diseases
Autoimmunity Reviews, Volume 13, Issues 4–5, Pages 331-594 (April–May 2014)
Edited by Yehuda Shoenfeld and M. Eric Gershwin
Diagnostic Criteria in Autoimmune Diseases
Journal of Autoimmunity, Volumes 48–49, Pages 1-152 (February–March 2014)
Edited by M. Eric Gershwin and Yehuda Shoenfeld